Heterologous Gene Expression from Transmissible Gastroenteritis Virus Replicon Particles by Curtis, K. M. et al.
JOURNAL OF VIROLOGY,
0022-538X/02/$04.000 DOI: 10.1128/JVI.76.3.1422–1434.2002
Feb. 2002, p. 1422–1434 Vol. 76, No. 3
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Heterologous Gene Expression from Transmissible
Gastroenteritis Virus Replicon Particles
Kristopher M. Curtis,1 Boyd Yount,2 and Ralph S. Baric1,2*
Department of Microbiology and Immunology, School of Medicine,1 and Department of Epidemiology,
Program of Infectious Diseases, School of Public Health,2 University of North Carolina
at Chapel Hill, Chapel Hill, North Carolina 27599-7400
Received 29 May 2001/Accepted 24 October 2001
We have recently isolated a transmissible gastroenteritis virus (TGEV) infectious construct designated
TGEV 1000 (B. Yount, K. M. Curtis, and R. S. Baric, J. Virol. 74:10600–10611, 2000). Using this construct, a
recombinant TGEV was constructed that replaced open reading frame (ORF) 3A with a heterologous gene
encoding green fluorescent protein (GFP). Following transfection of baby hamster kidney (BHK) cells, a
recombinant TGEV (TGEV-GFP2) was isolated that replicated efficiently and expressed GFP. Replicon con-
structs were constructed that lacked either the ORF 3B and E genes or the ORF 3B, E, and M genes [TGEV-
Rep(AvrII) and TGEV-Rep(EcoNI), respectively]. As the E and M proteins are essential for TGEV virion
budding, these replicon RNAs should replicate but not result in the production of infectious virus. Following
cotransfection of BHK cells with the replicon RNAs carrying gfp, GFP expression was evident by fluorescent
microscopy and leader-containing transcripts carrying gfp were detected by reverse transcription-PCR (RT-
PCR). Subsequent passage of cell culture supernatants onto permissive swine testicular (ST) cells did not
result in the virus, GFP expression, or the presence of leader-containing subgenomic transcripts, demonstrat-
ing the single-hit nature of the TGEV replicon RNAs. To prepare a packaging system to assemble TGEV
replicon particles (TGEV VRP), the TGEV E gene was cloned into a Venezuelan equine encephalitis (VEE)
replicon expression vector and VEE replicon particles encoding the TGEV E protein were isolated [VEE-
TGEV(E)]. BHK cells were either cotransfected with TGEV-Rep(AvrII) (E gene deletion) and VEE-TGEV(E)
RNA transcripts or transfected with TGEV-Rep(AvrII) RNA transcripts and subsequently infected with VEE
VRPs carrying the TGEV E gene. In both cases, GFP expression and leader-containing GFP transcripts were
detected in transfected cells. Cell culture supernatants, collected 36 h posttransfection, were passed onto
fresh ST cells where GFP expression was evident 18 h postinfection. Leader-containing GFP transcripts
containing the ORF 3B and E gene deletions were detected by RT-PCR. Recombinant TGEV was not released
from these cultures. Under identical conditions, TGEV-GFP2 spread throughout ST cell cultures, expressed
GFP, and formed viral plaques. The development of infectious TGEV replicon particles should assist studies
of TGEV replication and assembly as well as facilitate the production of novel swine candidate vaccines.
Transmissible gastroenteritis (TGE) is an economically im-
portant, acute enteric disease of swine, which is often 100%
fatal in newborn piglets (23, 24, 46). TGE virus (TGEV), the
causative agent of TGE, is a member of the Coronaviridae
family and the order Nidovirales. In addition to the Corona-
viridae, the order Nidovirales also includes the Arteriviridae
family, of which the swine pathogen porcine reproductive and
respiratory syndrome virus is a member (12, 18, 70). Despite
significant size differences (13 to 32 kb), the polycistronic
genome organization and regulation of gene expression from a
nested set of subgenomic mRNAs are similar for all members
of the order (18, 71).
TGEV possesses a single-stranded, positive-sense 28.5-kb
RNA genome enclosed in a helical nucleocapsid structure that is
surrounded by an envelope containing three viral proteins, includ-
ing the S glycoprotein, the membrane (M) glycoprotein and a
small envelope (E) protein (22, 25, 60, 61). Remarkably, only the
E and M proteins are absolutely required for particle formation,
defining a novel model for virion budding (27, 77). The TGEV
genome contains eight large open reading frames (ORFs), which
are expressed from full-length or subgenomic-length mRNAs
during infection (22, 68, 69). The 5-most 20 kb contains the
replicase genes in two ORFs, 1A and 1B, the latter of which is
expressed by ribosomal frameshifting (2, 22). The 3-most 9 kb
of the TGEV genome contains the structural genes, each pre-
ceded by a highly conserved intergenic sequence (IS) of 7 to 17
nucleotides (nt) in length that functions in the synthesis of each of
the subgenomic RNAs (14, 22, 25, 73). The subgenomic mRNAs
are arranged in a coterminal nested set structure from the 3 end
of the genome, and each contains a leader RNA sequence de-
rived from the 5 end of the genome. Although each mRNA is
polycistronic, the 5-most ORF is preferentially translated, neces-
sitating the synthesis of a distinct mRNA species for each ORF
(45, 49, 68, 69). Both full-length and subgenomic-length negative-
strand RNAs are also produced and have been implicated in
mRNA synthesis (8, 64, 66, 68, 69). Subgenomic RNA synthesis
occurs by a method of discontinuous transcription, most likely by
transcription attenuation during negative-strand synthesis (8, 64).
The coronavirus E and M proteins function in virion assem-
bly and release, which involve the constitutive secretory path-
way of infected cells. Coexpression of the E and M proteins
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results in virus-like particle formation in cells, defining a novel,
nucleocapsid-independent mechanism of enveloped-virus as-
sembly (77). The role of the E protein in virus assembly was
further confirmed by reverse genetic analysis using targeted
recombination (27). The TGEV M protein may serve to initi-
ate the viral particle assembly process through interactions
with genomic RNA and nucleoprotein in pre-Golgi compart-
ments (52). The precise role of E in the assembly and release
of coronavirus particles is not clear. Although an interaction
between the E and M proteins has not yet been demonstrated,
such an interaction likely occurs and would serve to facilitate
the budding of viral particles. Additionally, E protein has been
suggested to “pinch off the neck” of the assembled viral par-
ticles during the final stages of budding (77).
We have recently described a simple and rapid approach for
systematically assembling a full-length cDNA copy of the
TGEV genomic RNA from which infectious transcripts can be
produced (80). Our approach, as well as that of Almazan et al.
(2), will facilitate reverse genetic methods that impact all as-
pects of coronavirology. In this report, we describe the pro-
duction of recombinant TGEV expressing green fluorescent
protein (GFP) and the assembly of replicon RNAs encoding
GFP that contain deletions within the two structural genes
required for virion assembly and release (E and M). In addi-
tion, we have prepared a packaging system for TGEV replicons
using Venezuelan equine encephalitis (VEE) virus replicon
particles (VRPs) to express the TGEV E structural gene in
trans, which will assist studies of virion assembly and matura-
tion by allowing for the precise mapping of critical structural
protein residues and/or motifs. This TGEV replicon system
should prove useful for future studies of TGEV replication and
assembly as well as provide for novel candidate mucosal vac-
cines against important swine pathogens.
MATERIALS AND METHODS
Virus and cells. The Purdue strain of TGEV (ATCC VR-763) was obtained
from the American Type Culture Collection and passaged once in swine testic-
ular (ST) cells. ST cells were obtained from the American Type Culture Collec-
tion (ATCC 1746-CRL) and maintained in minimal essential medium containing
10% fetal clone II (HyClone Laboratories, Inc.) and supplemented with 0.5%
lactalbumin hydrolysate, 1 nonessential amino acids, 1 mM sodium pyruvate,
kanamycin (0.25 g/ml), and gentamicin (0.05 g/ml). Baby hamster kidney
(BHK) cells (BHK-21 [ATCC CCL10]) were maintained in alpha-minimal es-
sential medium containing 10% fetal calf serum supplemented with 10% tryptose
phosphate broth, kanamycin (0.25 g/ml), and gentamicin (0.05 g/ml). To
determine the effect of coinfection with TGEV and VEE VRPs on TGEV
growth rate, cultures of ST cells (5  105) were infected with wild-type TGEV
alone or with wild-type TGEV and VEE VRPs encoding a Norwalk-like virus
(VEE-NCFL) capsid antigen (ORF 2) at a multiplicity of infection (MOI) of 5
for 1 h (33). The cells were washed twice with phosphate-buffered saline (PBS)
to remove residual virus and VEE VRPs, and the cells were subsequently incu-
bated at 37°C in complete medium. At different times postinfection, progeny
virions were harvested and assayed by plaque assay in ST cells, as previously
described (80).
Recombinant DNA manipulations of TGEV F subclone. Plasmid DNAs were
amplified in Escherichia coli DH5 and purified with the QIAprep Miniprep kit
(Qiagen Inc., Valencia, Calif.). All enzymes were purchased from New England
BioLabs (Beverly, Mass.) and used according to the manufacturer’s directions.
DNA fragments were isolated from Tris-acetate-EDTA agarose gels (0.8%) with
the QIAEX II gel extraction kit (Qiagen Inc.). All DNA was visualized using
Dark Reader technology (Clare Chemical Research, Denver, Colo.) to prevent
UV-induced DNA damage that could impact subsequent manipulations, includ-
ing in vitro transcription. In our hands, increased concentrations of full-length
transcripts and increased transfection efficiencies were achieved after Dark
Reader technology was used to isolate the full-length TGEV cDNAs.
Six subgenomic cDNA clones (A to F) spanning the entire TGEV genome
were isolated using standard molecular techniques as previously described (80).
The 3 end of the TGEV genome, carrying the S, ORF 3A, ORF 3B, E, M, N,
and ORF S genes, is contained within the TGEV F subclone. nt 24828 to 25073
(GenBank accession no. AJ271965), corresponding to ORF 3A, were removed
and replaced with the ClaI and PflMI restriction sites using conventional recom-
binant DNA techniques such that the adjacent ORFs (S and 3B) were not
disrupted (62). The ClaI site was inserted just downstream of the 3A IS start,
while the PflMI site is located just upstream of the ORF 3B IS (Fig. 1a). The
mammalian codon-optimized version of the GFP gene was isolated from the
noncytopathic Sindbis virus vector pSINrep19/GFP (kindly provided by Charlie
Rice, Columbia University) and was inserted with a 5 20-nt N gene IS using the
ClaI/PflMI cloning site by standard recombinant DNA techniques (Fig. 1a) (62).
Clones were identified by DNA sequencing using an ABI model 377 automated
sequencer, and the resulting construct, TGEV pFiGFP2(PflMI), was subse-
quently used in the assembly of recombinant TGEV viral cDNA and as the
backbone for the construction of structural gene deletions (Fig. 1b).
Serial deletions within the TGEV structural gene region were generated from
the unique PflMI site at the very 3 end of the GFP gene and extended for various
distances toward the 3 end of the genome (Fig. 1b). TGEV pFiGFP2(PflMI) was
digested with PflMI and AvrII or EcoNI, treated with T4 DNA polymerase under
conditions in which the 533 exonuclease activity generated blunt ends (ac-
cording to the manufacturer’s directions) (New England BioLabs), and religated
using T4 DNA ligase. The unique AvrII site is located at nucleotide position
25866 within the E protein gene, and the unique EcoNI site is located at nucle-
otide position 26624 within the M protein gene (2). Clones containing each of the
deletions were identified by restriction digestion analysis and confirmed by DNA
sequencing using an ABI model 377 automated sequencer. The new TGEV F
fragments (FiGFP2-AvrII and FiGFP2-EcoNI) were subsequently utilized in the
assembly of the TGEV replicon constructs.
Assembly of full-length TGEV cDNAs. The six cDNA subclones spanning the
entire TGEV genome, including the FiGFP2(PflMI) and FiGFP2(PflMI) dele-
tion subclones, were used to assemble TGEV viral and replicon constructs,
respectively, as previously described (Fig. 1c) (80). The TGEV A fragment
contains a T7 promoter while the TGEV FiGFP2(PflMI), FiGFP2-AvrII, and
FiGFP2-EcoNI fragments terminate in a 25-nt poly(T) tract and a unique NotI
site at the 3 end, allowing for in vitro T7 transcription of capped, polyadenylated
transcripts. To assemble full-length TGEV recombinant virus and subgenomic
replicon cDNAs, plasmids were digested with BglI, BstXI, or NotI, and the
appropriately sized inserts were isolated from agarose gels. The TGEV A-B1,
B2-C, and DE-1–FiGFP2 fragments were ligated overnight at 4°C in the pres-
ence of T4 DNA ligase, according to the manufacturer’s directions. Systemati-
cally assembled products were isolated and extracted from agarose gels, and the
TGEV A-B1, B2-C, and DE-1–FiGFP2 fragments were religated overnight. The
final ligation products were purified by phenol-chloroform-isoamyl alcohol and
chloroform extraction, precipitated under isopropanol, and washed with 70 and
90% ethanol. Purified TGEV full-length viral and replicon cDNA constructs,
designated TGEV-GFP2, TGEV-Rep(AvrII), and TGEV-Rep(EcoNI), were
subsequently used for T7 in vitro transcription.
TGEV in vitro transcription and transfection. Capped runoff T7 transcripts
were synthesized in vitro from assembled TGEV and replicon cDNAs using the
mMessage mMachine kit as described by the manufacturer (Ambion, Austin,
Tex.), with certain modifications. TGEV RNA transcription reaction mixtures
(50-l volume) were prepared containing 7.5 l of a 30 mM GTP stock and
incubated at 37°C for 2 h. Similar reactions were performed using 1 l of PCR
amplicons carrying the TGEV N gene sequence and 1 g of pVR21-E1, each
containing a 2:1 ratio of cap analog to GTP. A portion of the RNA transcripts (5
l of the 50-l reaction volume) were treated with DNase I, denatured, and
separated in 0.5% agarose gels in Tris-acetate-EDTA buffer containing 0.1%
sodium dodecyl sulfate. The remaining RNA transcripts were directly electro-
porated into BHK cells. As a control, separate transcription reaction mixtures
were treated with RNase A for 15 min at room temperature prior to transfection.
BHK cells were grown to subconfluence (70%), trypsinized, washed twice with
PBS, and resuspended in PBS at a concentration of 107 cells/ml. RNA transcripts
were added to 800 l of the cell suspension (8  106 cells) in an electroporation
cuvette, and three electrical pulses of 850 V at 25 F were given with a Bio-Rad
Gene Pulser II electroporator. N gene transcripts (lacking the TGEV leader se-
quence) were included in all electroporations, as these transcripts may enhance the
recovery of infectious TGEV virions derived from the full-length cDNA construct,
TGEV 1000 (80). The BHK cells were either seeded alone or, in some instances,
mixed with 106 ST cells in a 75-cm2 flask and incubated at 37°C in 5% CO2. Aliquots
of cell culture supernatants were harvested 36 h postelectroporation, and fresh
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FIG. 1. Construction of TGEV replicon cDNAs. (a) TGEV F fragments. Structural genes are contained in the TGEV F fragment. FiGFP2
(PflMI) (5.6 kb) was constructed from the wild-type TGEV F fragment (5.1 kb) by the deletion of ORF 3A (nt 24828 to 25073) and the
insertion of GFP with a 5 20-nt N gene IS. Using this construct, we introduced deletions extending from the unique PflMI site at the very 3 end
of GFP to the unique AvrII (nucleotide position 25866) and EcoNI (nucleotide position 26935) sites present within the TGEV E and M genes,
respectively. (b) Sequence organization of GFP in FiGFP2(PflMI). GFP was inserted just downstream of the ORF 3A IS. The TGEV sequence
originating at the 3 end of the S gene (nt 24693) through the start of the GFP gene is shown, and the important IS and restriction sites are labeled.
(c) Strategy for assembling recombinant TGEV and replicon cDNAs. The six cDNA subclones (TGEV A, B1, B2, C, DE1, and F deletion
fragments) spanning the genome are flanked by unique interconnecting BglI and BstXI sites, allowing for directional assembly into a full-length
replicon cDNA by in vitro ligation (80). TGEV A contained a unique T7 start site at its 5 end, and the F deletion fragments (FiGFP2-AvrII and
FiGFP2-EcoNI) contain GFP and a 25-nt T tail, allowing for the synthesis of capped T7, polyadenylated transcripts in vitro.
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cultures of ST cells were infected for 1 h at room temperature and subsequently
incubated at 37°C in complete medium.
Analysis of GFP expression and RT-PCR to detect leader-containing sub-
genomic transcripts. At 18 h postelectroporation, transfected cultures were
analyzed for GFP expression by fluorescent microscopy using an Olympus model
inverted microscope. Total intracellular RNA was also harvested from trans-
fected cell cultures (pass 0) with Trizol reagent (Gibco BRL) and from cultures
inoculated with pass 0 supernatants (pass 1) at 36 h postinfection. The intra-
cellular RNA was used as a template for reverse transcription-PCR (RT-PCR)
using primer sets to detect leader-containing transcripts encoding GFP. RT
reactions were performed using Superscript II reverse transcriptase for 1 h at
42°C (250 mM Tris-HCl [pH 8.3], 375 mM KCl, 15 mM MgCl2, 0.1 M dithio-
threitol), as described by the manufacturer (Gibco BRL), prior to PCR ampli-
fication using Taq polymerase (Expand Long kit; Roche Biochemical). To detect
leader-containing GFP transcripts in TGEV-GFP2-infected cells, the 5 leader-
specific primer (nt 1 to 25) TGEV-L (5-CAC TAT AGA CTT TTA AAG TAA
AGT GAG TGT AGC-3) was used with the 3 primer F:5010() (5-ATT AAG
ATG CCG ACA CAC GTC-3), located within ORF 3B at position 24828. To
detect leader-containing GFP transcripts derived from replicon RNAs, two dif-
ferent primer sets were utilized. The 5 leader-specific primer, TGEV-L, was
used with the 3 primer ()E5546 (5-GTT AAT GAC CAT TCC ATT GTC-3),
located just downstream of the AvrII site within TGEV E at nucleotide position
25866, to amplify across the PflMI-AvrII deletion. To amplify across the PlfMI-
EcoNI deletion, the same 5 leader-specific primer (TGEV-L) was used with the
3 primer M6400() (5-CAA GTG TGT AGA CAA TAG TCC-3), located just
downstream of the EcoNI site within TGEV M at nucleotide position 26624.
Following 30 cycles of amplification (94°C for 25 s, 60°C for 25 s, 68°C for 90 s),
PCR products were separated on agarose gels and visualized by using Dark
Reader technology (Clare Chemical Research). All images were digitalized and
assembled by using Adobe Photoshop 5.5 (Adobe Systems, Inc.). Products were
subsequently isolated and subcloned directly into Topo XL TA cloning vectors
(Invitrogen) as described by the manufacturer. Colonies were isolated on Luria-
Bertani plates containing kanamycin (50 g/ml), and plasmid DNAs were se-
quenced using an ABI model 377 automated sequencer.
Recombinant VEE replicon construct. TGEV replicon helper constructs were
generated using pVR21, a VEE replicon vector kindly provided by Nancy Davis
and Robert Johnston (3). Using overlapping extension PCR, the TGEV E gene
was inserted just downstream of the subgenomic 26S promoter within the poly
cloning site of pVR21. Using the Expand Long Template PCR system (Roche
Molecular Biochemicals), the TGEV (Purdue strain) E gene was amplified from
the TGEV F fragment by 30 cycles of PCR (94°C for 25 s, 60°C for 25 s, 72°C for
1 min) by using the TGEV E(V) 5 primer (5-AGT CTA GTC CGC CAA
GAT GAC GTT TCC TAG GGC ATT G-3) and the AscI site-containing
TGEV E(V) 3 primer (5-GGC GCG CCT CAA GCA AGG AGT GCT CCA
TC-3). In addition, a segment of the pVR21 vector containing a unique SwaI site
followed by the 26S subgenomic promoter was amplified by PCR by using the
6198V primer (5-GCA AAG CTG CGC AGC TTT CC) with the ()7564V
primer (5-CAT CTT GGC GGA CTA GAC TAT GTC GTA GTC CAT TCA
GGT TAG CCG). Appropriately sized amplicons were isolated on agarose gels
and extracted as previously described (80).
The 5-most 19 nt of primer ()7546V were complementary to the 5-most 19
nt of the 5 TGEV E(V) primer, allowing for the adjoining of the two amplicons
by overlapping PCR. Using the Expand Long Template PCR system, reactions
were performed and consisted of 30 cycles of 94°C for 20 s, 58°C for 30 s, and
68°C for 2 min, with the first 5 cycles done in the absence of primers. The
resulting amplicon, containing unique SwaI and AscI restriction sites at its 5 and
3 ends, respectively, was isolated and purified as previously described. Following
AscI and SwaI restriction digest (unique to both the TGEV E amplicon and
pVR21), the TGEV E gene was inserted into the pVR21 vector. The resulting
recombinant VEE replicon vector (pVR21-E1) was cloned, and the sequence
was confirmed using an ABI model 377 automated sequencer.
A bipartite helper system consisting of two helper RNAs derived from the
V3014520-7505 monopartite helper was used for the construction of VEE
replicon particles (59). These helper RNAs express the individual capsid and
glycoprotein genes of VEE, thereby supplying the structural genes in trans.
Recombinant VEE VRP production. The recombinant VEE replicon construct
(pVR21-E1) was linearized at a site downstream of the VEE cDNA sequence by
NotI digestion, and T7 capped runoff transcripts were generated in vitro by using
the T7 mMessage mMachine kit as described by the manufacturer (Ambion).
Recombinant VEE replicon and helper RNAs were coelectroporated into BHK
cells and incubated at 37°C in 5% CO2 for 24 to 27 h. Cell culture supernatants
were harvested and clarified by centrifugation at 12,000  g for 15 min. Recom-
binant VEE VRPs (VEE-TGEV[E]) were partially purified, concentrated, and
resuspended in PBS as previously described (15). Although we were unable to
quantitatively identify the presence of VEE-TGEV(E) VRPs due to our lack of
anti-E antibody, a qualitative analysis was performed. BHK cells were infected
with purified VEE-TGEV(E) VRPs for 1 h at room temperature. VRP titers
were high as cytopathic effects were evident in 100% of the transfected cultures,
suggesting titers of 	108 VRP/ml, and transcripts encoding TGEV E were
present in infected cells (data not shown).
Packaging of TGEV replicon RNA. Two methods were used to supply TGEV
E in trans, allowing for the packaging of TGEV-Rep(AvrII) replicon RNA. In the
first method, TGEV-Rep(AvrII) replicon RNA and the helper RNA derived
from pVR21-E1 were coelectroporated into BHK cells. In the second method,
BHK cells were first electroporated with in vitro-transcribed TGEV-Rep(AvrII)
RNA, seeded onto 75-cm2 flasks of ST cells, and at 3 h postelectroporation,
subsequently infected with recombinant VEE-TGEV(E) VRPs for 1 h at room
temperature. Cultures were visualized for GFP expression by fluorescent micros-
copy at 18 h postelectroporation. Culture fluids were harvested 36 h post-
electroporation, and undiluted aliquots were inoculated onto fresh ST cell cul-
tures (75-cm2 flasks) for 1 h at room temperature. Successful packaging and
passing of TGEV-Rep(AvrII) replicon RNA were determined by GFP expres-
sion, and RT-PCR analysis was performed to detect leader-containing GFP
transcripts, as described above. In addition, RT-PCR was performed to detect
TGEV M and N gene leader-containing transcripts by using the TGEV-L 5
primer and the 3 primers TGEV-Mg (5-AGA AGT TTA GTT ATA CCA TAG
GCC TTT ATA CCA TAT GTA ATA ATT TTT CTT GCT CAC TC-3)
located at position 26870 within the M gene and TGEV-Ng (5-CCA CGC TTT
GGT TTA GTT CGT TAC CTC ATC AAT TAT CTC-3) located at position
28038 within the N gene, respectively. Briefly, RT reactions were performed by
using Superscript II reverse transcriptase for 1 h at 42°C (250 mM Tris-HCl [pH
8.3], 375 mM KCl, 15 mM MgCl2, 0.1 M dithiothreitol), as described by the
manufacturer (Gibco BRL), prior to 30 cycles of PCR amplification using Taq
polymerase (Expand Long kit; Roche Biochemical) (94°C for 25 s, 58°C for 25 s,
68°C for 1 min and 40 s). PCR products were separated on agarose gels, cloned,
and sequenced as previously described.
To verify the presence of single-hit TGEV-Rep(AvrII) particles and the lack of
recombinant TGEV with the wild-type phenotype, 60-mm2 cultures of ST cells
were infected for 1 h at room temperature with TGEV VRPs obtained from
previous TGEV-Rep(AvrII) packaging experiments (clarified and concentrated
by high-speed centrifugation as previously described [15]), overlaid with fresh
media, incubated at 37°C, and subsequently examined over a 72-h time period for
GFP expression by fluorescent microscopy as well as virus production by plaque
assay in ST cells. Under identical conditions, supernatants obtained from cell
cultures transfected with TGEV-GFP2 transcripts were passaged onto fresh ST
cells and examined for virus replication by GFP expression, for cytopathic effects,
and by plaque assay, as previously described.
RESULTS
Recombinant TGEV expressing GFP. Our method of devel-
oping recombinant TGEV and replicon constructs was based
on the same strategy previously used to assemble the full-
length cDNA construct TGEV 1000 (80). In this strategy, a
full-length cDNA construct is assembled from a series of six
cDNA subclones that span the entire TGEV genome (frag-
ments TGEV A, B1, B2, C, D/E, F), each flanked by restriction
sites that leave unique interconnecting junctions of 3 or 4 nt in
length (BglI and BstXI). These sticky ends are not complemen-
tary to most other sticky ends generated with the same enzyme
at other sites in the DNA, allowing for the systematic assembly
of TGEV cDNAs by in vitro ligation.
Six cDNA subclones that span the entire TGEV genome
were used in the assembly of recombinant TGEV cDNA
(TGEV-GFP2) (Fig. 1c). The 3 end of the TGEV genome,
including the S, ORF 3A, ORF 3B, E, M, N, and ORF S genes,
is carried by the 5.1-kb F fragment. To generate TGEV cDNA
constructs containing a reporter gene, the TGEV ORF 3A
gene was replaced with the GFP gene, as previous studies
suggest that TGEV ORFs 3A and 3B may encode luxury func-
tions unnecessary for virus replication (46, 49, 78). To poten-
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tially enhance GFP expression, we inserted a 20-nt N gene IS
(TGGTATAACTAAACTTCTAA) just upstream of the GFP
gene (Fig. 1a), as the transcripts initiated from this IS are the
most abundant throughout the TGEV replication cycle (35,
38). This new TGEV F fragment encoding GFP was desig-
nated FiGFP2(PflMI).
Appropriately sized fragments [TGEV A-FiGFP2(PflMI)]
were isolated by BglI and either BstXI or NotI digestion. Follow-
ing a series of in vitro ligations (80), full-length TGEV-GFP2
cDNA was isolated and subsequently used for in vitro transcrip-
tion. The TGEV A fragment contains a T7 promoter while the
TGEV FiGFP2(PflMI) fragment has a poly(T) tract at its very 3
end, allowing for in vitro T7 transcription of capped, polyadenyl-
ated mRNAs. Following in vitro transcription, full-length TGEV-
GFP2 transcripts were directly electroporated into 8  106 BHK
cells, and recombinant TGEV-GFP2 was harvested at 31 h post-
transfection. TGEV-GFP2 displayed growth kinetics similar to
those of wild-type TGEV generated from the TGEV 1000 infec-
tious construct, with both viruses growing to over 108 PFU/ml in
20 h (Fig. 2a). In addition, high levels of GFP expression from
TGEV-GFP2, but not from the wild-type virus, were evident by
fluorescence microscopy (Fig. 2b). Recombinant TGEV-GFP2 is
stable for at least 10 high-titer passages in ST cells, as demon-
strated by high levels of GFP expression (data not shown).
FIG. 2. Recombinant TGEV virus expressing GFP. (a) Cultures of
ST cells were infected with either recombinant TGEV-GFP2 virus or
the TGEV infectious construct (icTGEV) (80) at an MOI of 5 for 1 h
at room temperature. The inocula were removed, and the cultures
were incubated in complete medium at 37°C. Samples were harvested
at the indicated times and assayed by plaque assay in ST cells. (b)
Cultures of ST cells were infected as described for panel a. At 12 h
postinfection, GFP expression was observed by fluorescent microscopy
in TGEV-GFP2-infected cultures (B) but not in icTGEV-infected
cultures (A).
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Assembly of TGEV replicons encoding GFP. Our data dem-
onstrate that an ORF 3A deletion is not detrimental to stable
replication and passage of recombinant TGEV expressing
GFP. Consequently, replicon constructs were generated by
deleting the E and M structural genes from the previously
constructed FiGFP2(PflMI) F fragment (Fig. 1b). In the first
construct (pFiGFP2-AvrII), TGEV ORF 3B and the very 5
end of the E gene (first 10 nt), including the E gene IS and
ATG start codon, were removed by PflMI-AvrII digestion, re-
sulting in an 800-nt deletion from pFiGFP2(PflMI). In the
second construct (pFiGFP2-EcoNI), ORF 3B, E, and the 5-
most 508 nt of the M gene, including the M gene IS, were
removed by PflMI-EcoNI digestion, resulting in an 1.5-kb
deletion. These constructs were then used to assemble full-
length TGEV replicon cDNAs (Fig. 1c).
Replication competence and heterologous gene expression
from TGEV replicon RNAs. As with the construction of
TGEV-GFP2, six cDNA subclones that span the entire TGEV
genome were used in the assembly of TGEV-Rep constructs
(Fig. 1c). Appropriately sized fragments were isolated by BglI
and either BstXI or NotI digestion. Following a series of in
vitro ligations (80), full-length TGEV subgenomic replicons
[TGEV-Rep(AvrII) and TGEV-Rep(EcoNI)] were isolated
and subsequently used for in vitro transcription of TGEV rep-
licon RNAs (29.1 kb and 28.4 kb, respectively). Using tran-
scripts driven from various pSin replicons as a control, we
predict that these transcripts were likely of the appropriate
lengths (data not shown). Replicon RNA transcripts were di-
rectly electroporated into 8  106 BHK cells or treated with
RNase A prior to transfection, and the cultures were visualized
for GFP expression at 18 h posttransfection (Fig. 3a).
GFP expression was observed in 
1% of the cells trans-
fected with TGEV-Rep(AvrII) and TGEV-Rep(EcoNI)
RNAs (Fig. 3a), demonstrating that TGEV ORF 3A, ORF
3B, E, and M were not required for subgenomic mRNA syn-
thesis and GFP expression. Transcripts of TGEV-Rep(AvrII)
and TGEV-Rep(EcoNI) treated with RNase A prior to trans-
fection did not result in observable GFP expression. Leader-
containing subgenomic transcripts should be present that en-
code GFP and contain the appropriate deletions that were
introduced into the replicon cDNAs. Consequently, intracel-
lular RNA was isolated at 36 h postelectroporation and an-
alyzed by RT-PCR with primer pairs located within the leader
RNA sequence and downstream of the deletions in the TGEV-
Rep constructs. Appropriately sized amplicons of 850 bp
were generated from the TGEV-Rep(AvrII)- and TGEV-Rep
(EcoNI)-transfected cells (Fig. 3b), corresponding to leader-
containing GFP transcripts. Subsequently, the TGEV-Rep
(EcoNI) amplicon was gel extracted, cloned, and sequenced,
confirming the synthesis of leader-containing GFP transcripts
with the PflMI-EcoNI deletion that originated from the ORF
3A IS (see Fig. 7a and 7c). Identical results were seen following
TGEV-GFP2 infection, indicating that the 20-nt N gene IS was
silent in this configuration and that the natural ORF 3A IS was
preferentially used in subgenomic mRNA synthesis. In con-
trast, wild-type TGEV-infected cells yielded multiple ampli-
cons corresponding to leader-containing transcripts carrying
TGEV ORF 3A, ORF 3B, E, and M (data not shown). These
transcripts were not detected in TGEV-Rep(AvrII)- and TGEV-
Rep(EcoNI)-electroporated cells, respectively, as these genes
were completely or partially deleted in the TGEV-Rep con-
structs (Fig. 1b). Taken together, these data demonstrate the
synthesis of subgenomic mRNA and heterologous gene expres-
sion from the TGEV-Rep(AvrII) and TGEV-Rep(EcoNI) sub-
genomic replicon RNAs.
TGEV-Rep(AvrII) lacks all of ORF 3B and a portion of the
E gene and therefore should not produce infectious virions.
Successful assembly of infectious TGEV from this replicon
should be prevented on at least two levels. First, the E gene IS
and flanking sequences have been deleted in this replicon,
FIG. 3. Heterologous gene expression from TGEV replicon RNAs.
(a) Cultures of BHK cells were transfected with TGEV replicon RNAs
encoding GFP that contained ORF 3B and E (A) [TGEV-Rep(AvrII)
transcripts] or ORF 3B, E, and M gene deletions (C). Alternatively,
transcripts were treated with RNase prior to transfection into BHK
cells (B and D) [TGEV-Rep(AvrII) DNA and TGEV-Rep(EcoNI)
DNA only, respectively]. At 18 h posttransfection, GFP expres-
sion was observed by fluorescent microscopy. (b) Intracellular RNA
was isolated from transfected cell cultures and used as a template
for RT-PCR. Leader-containing GFP subgenomic transcripts were
detected using a 5 leader primer (TGEV-L) and 3 primers located
just downstream of the AvrII [()E5546] or EcoNI [M6400()]
sites. Appropriately sized amplicons of 850 bp were generated,
corresponding to transcripts encoding GFP. Cells transfected with
TGEV-Rep(AvrII) (A) or TGEV-Rep(EcoNI) (B) RNA are shown.
A 1-kb ladder is shown in both panels (lanes 1). Arrows indicate
leader-containing GFP amplicons (lanes 2).
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which should preclude the synthesis of E gene subgenomic
mRNA transcripts. Secondly, the E gene start codon has been
deleted, and the next possible ATG start codon is out of the E
gene reading frame at nucleotide position 25888 and would
potentially encode an irrelevant 14-amino-acid protein. How-
ever, one possible in-frame E gene start codon is located 33 bp
downstream of the PflMI-AvrII deletion, at nucleotide position
25899, and expression from this site would result in a truncated
E protein, with about a 17% (14 of 83 amino acids) deletion
from the N terminus, including residues within a putative
membrane anchor. Although unlikely, the expression of a bi-
ologically active, truncated E protein may result via read-
through from other TGEV mRNAs or from cryptic IS sites
that drive expression of a subgenomic mRNA encoding the E
protein, allowing for the assembly of infectious virions. We
think that this is unlikely, as cryptic subgenomic leader-con-
taining E transcripts were not detected by RT-PCR that would
encode this E protein truncation. To address whether small
amounts of truncated E are produced which function in virus
assembly and release, aliquots of cell culture supernatants
were harvested 36 h postelectroporation and passed onto
fresh cultures of ST cells (pass 1). By RT-PCR, there was no
evidence of virus replication. In addition, virus-induced cyto-
pathology and GFP expression were not apparent in these
cultures (data not shown).
Packaging of TGEV replicon RNA in virus particles. Previous
data indicate that the PflMI-AvrII deletion prevented E protein
function and the assembly of infectious virus. Consequently, E
protein provided in trans should complement the E gene deletion
and result in infectious TGEV VRPs. The VEE replicon system
has been used previously for the high-level expression of a num-
ber of heterologous genes (3, 11, 34, 58, 59, 67) and was used as
an efficient means for expressing the TGEV E protein in trans.
We hypothesized that VEE VRPs expressing TGEV E would
supply sufficient concentrations of E protein in trans to allow for
efficient assembly and release of packaged TGEV-Rep(AvrII)
VRPs (Fig. 4a). To determine the effect of VEE VRPs on TGEV
replication, cultures of ST cells were either infected with wild-type
TGEV alone or coinfected with VEE VRPs containing a G1
VEE-NCFL capsid gene (33) and wild-type TGEV. Progeny
TGEV virions were harvested at different times postinfection and
quantified by plaque assay in ST cells (Fig. 4b). Clearly, the
TGEV growth rate was not adversely affected by coinfection with
VEE VRPs. Similar results have been shown with another alpha-
virus, Sindbis virus, and the murine coronavirus mouse hepatitis
virus (MHV) (7).
The TGEV E gene was inserted into the VEE replicon
vector pVR21, just downstream of the subgenomic 26S promot-
er. The resulting construct, designated pVR21-E1, was subse-
quently used for the production of VEE VRPs expressing the
TGEV E protein [VEE-TGEV(E)]. Capped runoff TGEV-
Rep(AvrII) transcripts were electroporated into 8  106 BHK
cells (pass 0), seeded onto cultures of ST cells in 75-cm2 flasks
and then infected with VEE-TGEV(E) VRPs. Alternatively,
BHK cells were coelectroporated with TGEV-Rep(AvrII)- and
pVR21-E1-derived transcripts. In both experiments, GFP ex-
pression was evident by fluorescent microscopy by 18 h post-
transfection, demonstrating the subgenomic transcription and
heterologous gene expression from the TGEV-Rep(AvrII) ge-
nome in the presence of VEE replicon RNAs (Fig. 5). Cell
culture supernatants were harvested 36 h posttransfection
and used to inoculate fresh cultures of ST cells (pass 1) to
determine if the TGEV-Rep(AvrII) replicon RNA had been
packaged into TGEV VRPs. By 18 h postinfection, GFP
expression was observed in these pass 1 cultures (Fig. 5), con-
firming that replicon RNAs had been packaged into infectious
TGEV VRPs. However, TGEV VRP titers were low, esti-
mated to be 103 to 105 infectious units/ml by fluorescent mi-
croscopy, depending on the experiment.
TGEV VRPs should express leader-containing subgenomic
mRNAs encoding GFP and the various downstream ORFs,
including M and N. Following TGEV VRP infection, intracel-
lular RNA was isolated and subjected to RT-PCR by using
primer pairs in the leader RNA and downstream of the GFP,
M, and N genes. As in the previous TGEV-Rep(AvrII) exper-
iments, a leader-containing GFP amplicon of 850 bp was
generated (Fig. 6a) and sequenced to confirm the presence of
leader-containing GFP transcripts with the PflMI-AvrII dele-
tion (Fig. 7b). Leader-containing subgenomic transcripts were
also detected that contained the TGEV M and N genes, 900
bp and 1.2 kb, respectively (Fig. 6b), demonstrating that
transcripts for at least two of the structural genes were ex-
pressed in TGEV VRP-infected cells. Larger leader-contain-
ing amplicons were also observed and likely corresponded to
cryptic start sites noted within GFP as well as the larger GFP
leader-containing amplicons (Fig. 6b). These data demonstrate
the replication competence and heterologous gene expression
from packaged TGEV-Rep(AvrII) RNAs.
TGEV replicon particles function as single-hit virus vectors.
An important aspect of viral replicon particle systems, in terms
of future use as an expression vector for vaccine development,
is the lack of recombinant virus production. It is possible
that mutations may evolve which restore E protein expression
and function or recombinant TGEVs emerge following mixed
TGEV-Rep(AvrII) and VEE-TGEV(E) infection. To conclu-
sively demonstrate the lack of recombinant virus production
from the E deletion replicon RNA, ST cells were infected with
concentrated TGEV VRPs and examined for GFP expression
as well as virus production by plaque assay over a 72-h time
period (Fig. 8). Under identical conditions, parallel ST cell
cultures were infected with pass 0 supernatant (obtained from
transfected cell cultures) containing TGEV-GFP2. Expansion
of GFP expression was clearly observed in TGEV-GFP2-in-
fected cells (Fig. 8a, panels A to E) while no expansion was
noted in TGEV VRP-infected cells (Fig. 8a, panels F to J). In
fact, GFP expression in these TGEV VRP-infected cells even-
tually decreased after the 24-h time point and eventually dis-
appeared. Additionally, infectious TGEV particles were not
detected by plaque assay in TGEV VRP-infected cultures dur-
ing this same 72-h period (Fig. 8b), while infectious TGEV-
GFP2 virus rapidly reached titers of 2  106 PFU/ml by 48 h
postinfection under identical conditions. These data clearly
demonstrate the lack of revertant wild-type and recombinant
virus production from the TGEV-Rep(AvrII) VRP stocks.
DISCUSSION
In this report, we describe the assembly of recombinant
TGEVs and replicons that express GFP, which should prove
useful in furthering our understanding of coronavirus biology.
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The successful expression of heterologous genes from recom-
binant TGEVs and VRPs may also facilitate future vaccine
development against homologous and heterologous pathogens
(1, 3, 9, 10, 19–21, 34, 39, 41, 42, 47, 56–58, 67, 74, 75).
Importantly, the use of replicons as a vaccine delivery system
offers a number of important advantages over the use of live
attenuated virus vaccines, which are capable of independent
spread and recombination with wild-type virus populations.
Replicon vectors are an inherently safer alternative to the use
of live attenuated virus vaccines due to the lack of progeny
virus production. In addition, high-level expression of heterol-
ogous genes should result in the use of a relatively low dose of
VRPs for vaccination and immune induction.
TGEV vectors should provide an optional system for the
incorporation and expression of one or more foreign genes, as
coronaviruses contain a polycistronic genome organization and
synthesize multiple subgenomic-length mRNAs (25). It has
been shown that TGEV ORFs 3A and 3B likely encode luxury
functions that can be deleted without affecting infectivity or
replication in vitro and may serve as appropriate sites for the
insertion of heterologous genes into the TGEV genome (25,
FIG. 4. Strategy to assemble TGEV-Rep(AvrII) VRPs. (a) In the
full-length TGEV-Rep(AvrII) cDNA construct, ORF 3A has been
replaced with GFP, and ORF 3B and the 5 end of the E gene have
been deleted. To produce packaged replicon particles, replicon RNA-
transfected cells were infected with VEE VRPs expressing the TGEV
E protein [VEE-TGEV(E)]. Alternatively, TGEV-Rep(AvrII) repli-
con RNAs can be coelectroporated with pVR21-E1-derived tran-
scripts. TGEV VRPs should be released from cells that can be used as
single-hit expression vectors. (b) Cultures of ST cells were infected
with either wild-type (wt) TGEV alone or with TGEV and VEE VRPs
expressing a G1 Norwalk-like virus capsid (wt  VEE) at an MOI of 5 for
1 h at room temperature. The inocula were removed, and the cultures
were incubated in complete medium at 37°C. Samples were harvested
at the indicated times and assayed by plaque assay in ST cells.
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46, 49, 76, 78). In contrast to arteriviruses, the TGEV IS sites
rarely overlap (or overlap slightly) with upstream ORFs, sim-
plifying the design and expression of foreign genes from down-
stream IS sites (14, 22, 73). The helical nucleocapsid structure
of TGEV will also likely minimize packaging constraints and
allow for the expression of multiple large genes from a single
construct (25, 45, 61). Importantly, recombinant TGEV VRPs
could be readily targeted to other mucosal surfaces in swine or
to other species by simple replacements in the S glycoprotein
gene, which has been shown to determine tissue and species
tropism (16, 44, 63, 72). For these reasons, TGEV VRPs may
provide a novel approach for the development of combination
vaccines in a variety of mammalian hosts.
We have successfully inserted and expressed GFP from the
TGEV genome, demonstrating the feasibility of using TGEV-
based replicon vectors for heterologous gene expression.
Efficient self-replication of in vitro-transcribed recombinant
TGEV and replicon RNAs was demonstrated by GFP expres-
sion, the presence of leader-containing subgenomic transcripts,
and the production of infectious recombinant virus and VRPs.
These data support previous results suggesting that the TGEV
ORFs 3A and 3B were not required for virus replication in
vitro, although these genes may confer subtle fitness advan-
tages that cannot be detected by these assays (46, 49, 78). It
should also be possible to determine the minimal TGEV rep-
licon size by serially deleting each of the downstream ORFs.
However, this may be complicated by the requirement of RNA
secondary structures that may be essential for genome repli-
cation or subgenomic RNA synthesis (36, 37, 79). As has been
previously reported, efficient TGEV RNA transfection and
expression in cells were dependent upon the coelectroporation
of N transcripts (78). Because the nucleocapsid protein inter-
acts with leader and negative-strand RNA and colocalizes with
the viral polymerase sites of RNA synthesis, it is possible that
the N protein may function as part of the transcription complex
in some undetermined manner (6, 17). Replicon constructs
containing N gene deletions may facilitate studies of the pos-
sible N gene function(s) in TGEV replication.
Using synthetic defective-interfering (DI) RNA genomes,
some groups have reported that downstream ISs suppress tran-
scription from upstream ISs (40, 43). In addition, data suggest
that the N gene IS is the strongest initiator of TGEV sub-
genomic RNA transcription (35, 38). In our recombinant virus
and replicon RNAs, GFP subgenomic mRNA synthesis was
initiated from the normal ORF 3A IS rather than from the
20-nt N gene IS that has been duplicated just upstream of gfp
(Fig. 7a). Our results do not necessarily contradict earlier re-
ports, as in this context the N gene IS function was silent and
would not display the reported phenotypes. Also, fundamental
differences exist between the two systems used in these analy-
ses (DI versus nearly full-length replicon), including the rapid
replication of small 2- to 3-kb DI RNAs and IS presentation,
compared with 28.5-kb genome-length RNAs. For example,
experiments utilizing DI systems involved IS elements within
primary and secondary flanking genome sequence contexts
that were not authentic, while the ISs in our recombinant
viruses and replicons closely approximate the wild-type TGEV
genome. Our data suggest that IS location and flanking se-
quences likely have an impact on gene expression, especially in
promoter proximal locations, which are fundamentally differ-
ent in the two systems. The simplest interpretation of our data
is that the random insertion of a large 20-nt IS element is not
sufficient to initiate TGEV subgenomic mRNA synthesis un-
less this IS is provided to the viral transcriptional machinery in
an appropriate context that as of yet remains unknown. Our
FIG. 5. TGEV-Rep(AvrII) VRPs. Transfected cultures displayed
GFP expression at 18 h posttransfection (A) [TGEV-Rep(AvrII)
pass 0]. Supernatants were harvested 36 h posttransfection and used
to infect fresh cultures of ST cells for 1 h at room temperature. At 18
h postinfection, GFP expression was observed by fluorescent micros-
copy in these pass 1 cultures (C and D). (C) TGEV VRP production
following coelectroporation with VEE-E RNAs [TGEV-Rep(AvrII)
plus E protein transcripts pass 1]; (D) TGEV VRP production follow-
ing infection with VEE VRPs encoding the E protein [TGEV-Rep
(AvrII) plus VEE-TGEV(E) pass 1]. Passage of supernatants from
cells transfected with TGEV-Rep(AvrII) transcripts without expres-
sion of the E protein in trans did not result in detectable GFP expres-
sion (B) [TGEV-Rep(AvrII) without E protein pass 1].
FIG. 6. Leader-containing subgenomic transcripts are present in
cultures infected with TGEV VRPs. Intracellular RNA was isolated
from cell cultures infected with pass 0 supernatants and used as a
template for RT-PCR to detect leader-containing GFP, M, and N
subgenomic transcripts using a 5 leader primer (TGEV-L) and 3
primers located just downstream of each respective gene. (A) An
appropriately sized amplicon of 850 bp was generated (indicated by
an arrow), corresponding to leader-containing transcripts encoding
GFP (lane 1). Lane 2 shows a 1-kb ladder. (B) In addition, amplicons
of 900 bp and 1.2 kb were generated, corresponding to leader-
containing M and N gene mRNA transcripts, respectively. The arrows
correspond to leader-containing M (lane 2) or N (lane 3) transcripts.
A 1-kb ladder is shown in lane 1.
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data, as well as that obtained concerning bovine coronavirus
(54), lead us to hypothesize that TGEV subgenomic RNA
transcription may be mediated by long-range RNA and/or ribo-
nucleoprotein interactions, which are most definitely depen-
dent on higher orders of genome structure.
We noted smaller leader-containing RNAs, indicating the
presence of cryptic transcription start sites within GFP. This
phenomenon was previously observed following expression of
GFP from the MHV genome (26, 65). Both the TGEV and
MHV genomes contain a number of atypical start sites that
result in the transcription of aberrant subgenomic RNAs (data
not shown) (26). These data further substantiate our conclu-
sion that the insertion of IS elements may not be enough to
direct TGEV subgenomic mRNA synthesis and that genome
location, flanking sequence, and secondary sequence likely
function in this process.
The VEE, Kunjin, and Sindbis replicon packaging systems
involve the cotransfection of replicon and helper RNAs that
express the structural genes (59). In addition to this method,
replicon RNAs have been packaged by the expression of struc-
tural genes in trans from wild-type or mutated virus (53, 56).
An important concern with these types of replicon systems is
the production of recombinant virus, especially when consid-
ering the development of a replicon particle vaccine. Recom-
binant viruses have been isolated from Sindbis virus and VEE
virus replicon systems that may be the result of recombination
between replicon and helper RNAs and/or copackaging of
replicon and helper RNAs into the same VRP (28, 30, 59).
Coronaviruses undergo homologous recombination at high
frequencies during mixed infection, which presents a signifi-
cant concern for the production and use of TGEV replicons (5,
29, 50). Our TGEV replicon packaging system involves the use
of an unrelated virus vector (VEE). In our system, TGEV-Rep
(AvrII) RNAs were packaged by the expression of TGEV E in
trans from VEE VRPs as well as from pVR21-E1-derived
helper RNA transcripts. Because the TGEV replicon packag-
ing system involves the use of an unrelated virus vector (VEE),
the possibility of a recombination event between replicon and
helper RNAs may be reduced. In addition, the TGEV E gene
carried in the VEE replicon construct lacks an appropriate IS,
which is necessary for the initiation of subgenomic RNA tran-
scription. As this same IS is deleted in the TGEV-Rep(AvrII)
construct, expression of TGEV helper genes that are recom-
bined into TGEV replicon RNAs should be minimized in our
system. Although recombinant wild-type TGEV was not de-
tected, this concern could also be reduced by the inclusion of
attenuating mutations in the helper proteins and/or the engi-
neering of a bipartite replicon and helper system (TGEV E
and M structural proteins) (59). Nevertheless, the possibility of
RNA recombination between the replicon RNA and wild-type
virus cannot be eliminated and remains an important issue
requiring additional analysis.
FIG. 7. Sequence analysis of leader-containing amplicons encoding GFP. TGEV-Rep(AvrII) and TGEV-Rep(EcoNI) leader-containing am-
plicons were isolated from agarose gels and subcloned into Topo II TA cloning vectors. Inserts were sequenced using universal primers and an
automated sequencer. (A) Sequence of the 5 end of GFP amplicons generated from TGEV-Rep(EcoNI)-transfected cells, indicating that the
leader-containing transcripts initiated from the TGEV ORF 3A IS. (B) Leader-containing GFP transcripts with the PflMI-AvrII deletion derived
from TGEV-Rep(AvrII) VRP-infected cells. (C) Leader-containing GFP transcripts with the PflMI-EcoNI deletion derived from TGEV-Rep
(EcoNI)-transfected cells. Underlined bases correspond to the GFP stop codon, and the shaded bases correspond to the deletion and blunt-end
ligation sites.
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Another advantage to the use of VEE replicon vectors to ex-
press TGEV structural genes is the possibility of developing com-
bination vaccines. Dendritic cells, which are professional antigen-
presenting cells and potent inducers of T-cell responses to viral
antigens, are preferred targets of VEE and VRP infection, while
TGEV targets the mucosal surfaces of the respiratory and gas-
trointestinal tract (4, 23, 25, 48). As the VEE and TGEV replicon
RNAs synergistically interact, two-vector vaccine systems are fea-
sible that may result in increased immunogenicity when compared
with either vector alone. Combination prime-boost vaccines (e.g.,
DNA immunization and vaccinia virus vectors) have dramatically
enhanced the immune response (notably cellular responses)
against target papillomavirus and lentivirus antigens compared to
single-immunization regimens (13, 31, 32, 55). Using different
recombinant viral vectors (influenza and vaccinia) to prime and
boost may also synergistically enhance the immune response,
sometimes by an order of magnitude or more (31).
Our strategy for the assembly of TGEV replicon constructs was
based on the use of six cDNA subclones that span the entire
length of the TGEV genome, designated fragments A to F, which
can be systematically ligated in vitro into a full-length cDNA (80).
This strategy is capable of circumventing problems associated
FIG. 8. TGEV replicon particles function as single-hit virus vec-
tors. Cultures of ST cells were infected for 1 h at room temperature
with either concentrated TGEV VRPs or supernatant from TGEV-
GFP2-transfected cells. (a) Cultures were then examined over a 72-h
time period for GFP expression by fluorescent microscopy. Expansion
of GFP expression was observed in TGEV-GFP2-infected cells (panels
A to E) while no expansion was noted in TGEV VRP-infected cells
(panels F to J). (b) In addition, supernatants were harvested from the
TGEV-GFP2- and TGEV VRP-infected cultures and assayed by
plaque assay in ST cells. Symbols: , TGEV-GFP2; , TGEV-VRP.
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with genome size constraints as well as regions of chromosomal
instability, while allowing for simple reverse genetic applications.
Full-length TGEV cDNA constructs must be synthesized de novo
and do not exist intact in bacterial vectors, circumventing prob-
lems with sequence instability. However, this did not restrict the
applicability of our approach. In fact, the separation of the rep-
licon constructs into distinct fragments allows for genetic ma-
nipulation of independent subclones, thereby minimizing the
occurrence of spurious mutations that arise during recombi-
nant DNA manipulation. Because replicon cDNAs are con-
sumed during in vitro transcription in this strategy, a weakness
of our approach is that the full-length replicon cDNAs are
consumed with use and must be continually rebuilt. However,
replicon cDNAs will likely be stable in bacterial artificial chro-
mosome vectors after reverse genetic manipulations, prevent-
ing the need for repetitive de novo synthesis by engineered
constructs (2, 51).
The synthesis of large RNA transcripts (27 to 29 kb) in
vitro is problematic, and the electroporation of such large
RNA constructs has also proven difficult, resulting in a 
1%
transfection efficiency. This low efficiency of transfection will
likely limit the production of TGEV VRPs and their use as
vaccine vectors. However, transfecting cells with helper pack-
aging constructs and subsequently passing the TGEV VRPs in
the presence of VEE-TGEV(E) VRPs may address this issue.
In this way, VRPs can be amplified and high concentrations
may amplify replicon titers for future applications. In addition,
the use of a DNA launch platform, such as with a cytomega-
lovirus promoter, may overcome the problems associated with
our RNA launch system.
In summary, we have developed efficient RNA-based recom-
binant TGEV and replicon particles capable of expressing
GFP in cultured cells. Our data are in agreement with other
studies showing that the TGEV E protein is absolutely essen-
tial for coronavirus particle assembly (27, 77). This TGEV
replicon system allows for the dissociation of RNA replication
from virion assembly and should provide a powerful model
system to independently address questions of coronavirus
RNA synthesis, polymerase function, assembly, and release. In
addition, recombinant TGEVs and VRPs may facilitate the
production of novel swine candidate vaccines.
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